Surmodics (Surmodics) Change In Receivables

: $-5.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

Surmodics's change in receivables for the quarter that ended in Dec. 2023 was $-3.4 Mil. It means Surmodics's Accounts Receivable increased by $3.4 Mil from Sep. 2023 to Dec. 2023 .

Surmodics's change in receivables for the fiscal year that ended in Sep. 2023 was $-1.0 Mil. It means Surmodics's Accounts Receivable increased by $1.0 Mil from Sep. 2022 to Sep. 2023 .

Surmodics's Accounts Receivable for the quarter that ended in Dec. 2023 was $12.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Surmodics's Days Sales Outstanding for the three months ended in Dec. 2023 was 38.59.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Surmodics's liquidation value for the three months ended in Dec. 2023 was $-6.0 Mil.

Surmodics Change In Receivables Historical Data

The historical data trend for Surmodics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

-1.63

3.46

-2.48

-1.52

-0.98

Surmodics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															0.55	-2.89	0.52	0.85	-3.43

Surmodics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.0 Mil.

Surmodics (NAS:SRDX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Surmodics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	12.919	/	30.552	*	91
=	38.59

2. In Ben Graham's calculation of liquidation value, Surmodics's accounts receivable are only considered to be worth 75% of book value:

Surmodics's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	35.174	-	58.09	+	0.75 * 12.919	+	0.5 * 14.438
=	-6.0

Surmodics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Surmodics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Surmodics (Surmodics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

SU6:Germany

Address

9924 West 74th Street, Eden Prairie, MN, USA, 55344

Website

https://www.surmodics.com

Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Executives

Jose H Bedoya	director
David Dantzker	other: See Explanation of Responses	80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr	director
Gary R Maharaj	director, officer: President & CEO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich	officer: VP, Corp Dev & Strat Planning	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson	officer: General Manager
John D. Manders	officer: Corporate Controller	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber	officer: Sr. VP of Legal, GC and Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana	officer: VP, Clinical Affairs	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine	director	1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides	officer: Senior VP and CMO	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton	officer: VP of Research and Development	6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight	director	9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips	officer: Dep. Gen. Counsel & Corp. Sec.	9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens	officer: General Manager - IVD	9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344